Danielle B Tometich1, Brent J Small2, Judith E Carroll3, Wanting Zhai4, George Luta4, Xingtao Zhou4, Lindsay C Kobayashi4, Tim Ahles5, Andrew J Saykin6, Jonathan D Clapp7, Heather S L Jim8, Paul B Jacobsen9, Arti Hurria10, Deena Graham11, Brenna C McDonald6, Neelima Denduluri12, Martine Extermann8, Claudine Isaacs4, Asma Dilawari4, James Root5, Christine Rini13, Jeanne S Mandelblatt4. 1. Indiana University-Purdue University Indianapolis, Indianapolis, Indiana, USA. Electronic address: dbtometi@iupui.edu. 2. Moffitt Cancer Center, Tampa, Florida, USA; University of South Florida, Tampa, Florida, USA. 3. University of California Los Angeles and Jonsson Comprehensive Cancer Center, Los Angeles, California, USA. 4. Georgetown University and Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA. 5. Memorial Sloan Kettering Cancer Center, New York City, New York, USA. 6. Indiana University School of Medicine and Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA. 7. University of South Florida, Tampa, Florida, USA; Georgetown University and Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA. 8. Moffitt Cancer Center, Tampa, Florida, USA. 9. National Cancer Institute, Bethesda, Maryland, USA. 10. City of Hope Comprehensive Cancer Center, Duarte, California, USA. 11. John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA. 12. US Oncology of Virginia, Arlington, Virginia, USA. 13. Georgetown University and Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Abstract
CONTEXT: Symptoms affect quality of life (QOL), functional status, and cognitive function in cancer survivors, but older survivors are understudied. OBJECTIVES: The objectives of this study were to identify prototypical presystemic therapy psychoneurological symptom clusters among older breast cancer survivors and determine whether these symptom clusters predicted cognition and QOL over time. METHODS: Women with newly diagnosed nonmetastatic breast cancer (n = 319) and matched noncancer controls (n = 347) aged 60+ years completed questionnaires and neuropsychological tests before systemic therapy and 12 and 24 months later. Latent class analysis identified clusters of survivors based on their pretherapy depression, anxiety, fatigue, sleep disturbance, and pain. Linear mixed-effects models examined changes in objective cognition, perceived cognition, and functional status (Instrumental Activities of Daily Living disability, functional well-being, and breast cancer-specific QOL) by group, controlling for covariates. RESULTS: Nearly one-fifth of older survivors were classified as having high pretherapy symptoms (n = 51; 16%); the remainder had low symptoms (n = 268; 84%); both groups improved over time on all outcomes. However, compared to the low symptom group and controls, survivors with high symptoms had lower baseline objective cognition and lower perceived cognition at baseline and 24 months, lower functional well-being at baseline and 12 months, greater Instrumental Activities of Daily Living disability at baseline, and lower breast cancer-specific QOL at all time points (all P < 0.05). CONCLUSION: Nearly one-fifth of older breast cancer survivors had high psychoneurological symptoms at diagnosis, which predicted clinically meaningful decrements in perceived cognition and function in the first 24 months after diagnosis. Pretreatment psychoneurological symptom clusters could identify survivors for monitoring or intervention.
CONTEXT: Symptoms affect quality of life (QOL), functional status, and cognitive function in cancer survivors, but older survivors are understudied. OBJECTIVES: The objectives of this study were to identify prototypical presystemic therapy psychoneurological symptom clusters among older breast cancer survivors and determine whether these symptom clusters predicted cognition and QOL over time. METHODS: Women with newly diagnosed nonmetastatic breast cancer (n = 319) and matched noncancer controls (n = 347) aged 60+ years completed questionnaires and neuropsychological tests before systemic therapy and 12 and 24 months later. Latent class analysis identified clusters of survivors based on their pretherapy depression, anxiety, fatigue, sleep disturbance, and pain. Linear mixed-effects models examined changes in objective cognition, perceived cognition, and functional status (Instrumental Activities of Daily Living disability, functional well-being, and breast cancer-specific QOL) by group, controlling for covariates. RESULTS: Nearly one-fifth of older survivors were classified as having high pretherapy symptoms (n = 51; 16%); the remainder had low symptoms (n = 268; 84%); both groups improved over time on all outcomes. However, compared to the low symptom group and controls, survivors with high symptoms had lower baseline objective cognition and lower perceived cognition at baseline and 24 months, lower functional well-being at baseline and 12 months, greater Instrumental Activities of Daily Living disability at baseline, and lower breast cancer-specific QOL at all time points (all P < 0.05). CONCLUSION: Nearly one-fifth of older breast cancer survivors had high psychoneurological symptoms at diagnosis, which predicted clinically meaningful decrements in perceived cognition and function in the first 24 months after diagnosis. Pretreatment psychoneurological symptom clusters could identify survivors for monitoring or intervention.
Authors: Bryce B Reeve; Sandra A Mitchell; Amylou C Dueck; Ethan Basch; David Cella; Carolyn Miller Reilly; Lori M Minasian; Andrea M Denicoff; Ann M O'Mara; Michael J Fisch; Cynthia Chauhan; Neil K Aaronson; Corneel Coens; Deborah Watkins Bruner Journal: J Natl Cancer Inst Date: 2014-07-08 Impact factor: 13.506
Authors: Victoria L Champion; Lynne I Wagner; Patrick O Monahan; Joanne Daggy; Lisa Smith; Andrea Cohee; Kim W Ziner; Joan E Haase; Kathy D Miller; Kamnesh Pradhan; Frederick W Unverzagt; David Cella; Bilal Ansari; George W Sledge Journal: Cancer Date: 2014-05-28 Impact factor: 6.860
Authors: Charles S Cleeland; Musa Mayer; Nancy A Dreyer; Yeun Mi Yim; Elaine Yu; Zhaohui Su; Yong Mun; Jeff A Sloan; Peter A Kaufman Journal: Breast Date: 2014-09-03 Impact factor: 4.380
Authors: Miyuki Ono; James M Ogilvie; Jennifer S Wilson; Heather J Green; Suzanne K Chambers; Tamara Ownsworth; David H K Shum Journal: Front Oncol Date: 2015-03-10 Impact factor: 6.244
Authors: Anna Barata; Aasha I Hoogland; Anuhya Kommalapati; Jennifer Logue; Taylor Welniak; Kelly A Hyland; Sarah L Eisel; Brent J Small; Reena V Jayani; Margaret Booth-Jones; Laura B Oswald; Brian D Gonzalez; Kedar S Kirtane; Michael D Jain; Sepideh Mokhtari; Julio C Chavez; Aleksandr Lazaryan; Bijal D Shah; Frederick L Locke; Heather S L Jim Journal: Transplant Cell Ther Date: 2022-05-14
Authors: Carmen Kohler; Ming Chang; Yu-Yin Allemann-Su; Marcus Vetter; Miyeon Jung; Misook Jung; Yvette Conley; Steven Paul; Kord M Kober; Bruce A Cooper; Betty Smoot; Jon D Levine; Christine Miaskowski; Maria C Katapodi Journal: J Pain Symptom Manage Date: 2020-01-15 Impact factor: 3.612
Authors: Kathleen Van Dyk; Xingtao Zhou; Brent J Small; Jaeil Ahn; Wanting Zhai; Tim Ahles; Deena Graham; Paul B Jacobsen; Heather Jim; Brenna C McDonald; Kelly Nudelman Holohan; Sunita K Patel; G William Rebeck; James C Root; Andrew J Saykin; Harvey Jay Cohen; Jeanne S Mandelblatt; Judith E Carroll Journal: JNCI Cancer Spectr Date: 2021-01-27
Authors: Rebecca A Harrison; Noha Sharafeldin; Jennie L Rexer; Brennan Streck; Melissa Petersen; Ashley M Henneghan; Shelli R Kesler Journal: Oncologist Date: 2021-07-12
Authors: Adele Crouch; Victoria L Champion; Frederick W Unverzagt; Susan J Pressler; Lesa Huber; Lyndsi R Moser; David Cella; Diane Von Ah Journal: J Geriatr Oncol Date: 2021-07-08 Impact factor: 3.599
Authors: Jeanne S Mandelblatt; Wanting Zhai; Jaeil Ahn; Brent J Small; Tim A Ahles; Judith E Carroll; Neelima Denduluri; Asma Dilawari; Martine Extermann; Deena Graham; Arti Hurria; Claudine Isaacs; Paul B Jacobsen; Heather S L Jim; George Luta; Brenna C McDonald; Sunita K Patel; James C Root; Andrew J Saykin; Danielle B Tometich; Xingtao Zhou; Harvey J Cohen Journal: Cancer Date: 2019-12-20 Impact factor: 6.921